Critical Biologics raises $7,000,000

Critical Biologics Corporation (CBC), a private company, today announced it has closed a Series ‘A’ financing with a $7 million investment — commercialize diagnostics and therapeutics that predict and regulate inflammatory responses to life-threatening diseases. In particular, CBC is focused on a theranostic approach to treat critical care patients with low plasma gelsolin levels at high risk of life-threatening complications.